IN2014DN04587A - - Google Patents
Info
- Publication number
- IN2014DN04587A IN2014DN04587A IN4587DEN2014A IN2014DN04587A IN 2014DN04587 A IN2014DN04587 A IN 2014DN04587A IN 4587DEN2014 A IN4587DEN2014 A IN 4587DEN2014A IN 2014DN04587 A IN2014DN04587 A IN 2014DN04587A
- Authority
- IN
- India
- Prior art keywords
- compounds
- methods
- administering
- acceptable salts
- compositions containing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55814104P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/011313 WO2005097757A2 (en) | 2004-04-01 | 2005-04-01 | Nucleoside derivatives and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN04587A true IN2014DN04587A (enrdf_load_stackoverflow) | 2015-07-10 |
Family
ID=34979006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4587DEN2014 IN2014DN04587A (enrdf_load_stackoverflow) | 2004-04-01 | 2005-04-01 |
Country Status (15)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9315534B2 (en) * | 2007-08-10 | 2016-04-19 | Board Of Regents Of The University Of Nebraska | Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents |
| US20120269725A1 (en) * | 2009-12-23 | 2012-10-25 | Janine Baranowska-Kortylewicz | Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer |
| ES2678085T3 (es) * | 2013-03-15 | 2018-08-08 | Rexahn Pharmaceuticals, Inc. | Proceso para la preparación de 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1H-pirimidin-2-ona |
| EP4008321A1 (en) * | 2015-06-09 | 2022-06-08 | Ocuphire Pharma, Inc. | Fluorocyclopentenylcytosine for treating tumour |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6187674A (ja) * | 1984-10-06 | 1986-05-06 | Yoshitomi Pharmaceut Ind Ltd | シクロペンテン環を有する新規ヌクレオシド |
| US4975434A (en) * | 1986-05-27 | 1990-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antiviral and anticancer cyclopentenyl cytosine |
| AU2002228749B2 (en) | 2000-10-18 | 2008-04-24 | Pharmasset Inc | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| TWI299664B (en) * | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
-
2005
- 2005-04-01 JP JP2007506347A patent/JP5001832B2/ja not_active Expired - Lifetime
- 2005-04-01 ES ES05733004T patent/ES2334803T3/es not_active Expired - Lifetime
- 2005-04-01 US US11/095,686 patent/US7405214B2/en not_active Expired - Lifetime
- 2005-04-01 IN IN4587DEN2014 patent/IN2014DN04587A/en unknown
- 2005-04-01 AT AT05733004T patent/ATE453628T1/de not_active IP Right Cessation
- 2005-04-01 KR KR1020067022856A patent/KR100926596B1/ko not_active Expired - Lifetime
- 2005-04-01 BR BRPI0509553A patent/BRPI0509553B8/pt active IP Right Grant
- 2005-04-01 CN CN2010105546004A patent/CN102091072A/zh active Pending
- 2005-04-01 PL PL05733004T patent/PL1732902T3/pl unknown
- 2005-04-01 AU AU2005230676A patent/AU2005230676B2/en not_active Expired
- 2005-04-01 MX MXPA06011141A patent/MXPA06011141A/es active IP Right Grant
- 2005-04-01 DE DE602005018620T patent/DE602005018620D1/de not_active Expired - Lifetime
- 2005-04-01 CA CA2562965A patent/CA2562965C/en not_active Expired - Lifetime
- 2005-04-01 CN CN2005800178253A patent/CN1980898B/zh not_active Expired - Fee Related
- 2005-04-01 EP EP05733004A patent/EP1732902B1/en not_active Expired - Lifetime
- 2005-04-01 WO PCT/US2005/011313 patent/WO2005097757A2/en active Application Filing
-
2012
- 2012-03-12 JP JP2012054597A patent/JP2012107072A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0509553B8 (pt) | 2021-05-25 |
| PL1732902T3 (pl) | 2010-06-30 |
| KR100926596B1 (ko) | 2009-11-11 |
| DE602005018620D1 (de) | 2010-02-11 |
| US7405214B2 (en) | 2008-07-29 |
| ES2334803T3 (es) | 2010-03-16 |
| CN1980898B (zh) | 2011-01-12 |
| BRPI0509553A (pt) | 2007-09-18 |
| AU2005230676B2 (en) | 2010-10-07 |
| JP5001832B2 (ja) | 2012-08-15 |
| JP2012107072A (ja) | 2012-06-07 |
| KR20070012685A (ko) | 2007-01-26 |
| WO2005097757A2 (en) | 2005-10-20 |
| CA2562965C (en) | 2013-10-29 |
| CN102091072A (zh) | 2011-06-15 |
| EP1732902A2 (en) | 2006-12-20 |
| WO2005097757A3 (en) | 2005-12-08 |
| US20050222185A1 (en) | 2005-10-06 |
| ATE453628T1 (de) | 2010-01-15 |
| JP2007531736A (ja) | 2007-11-08 |
| AU2005230676A1 (en) | 2005-10-20 |
| CA2562965A1 (en) | 2005-10-20 |
| BRPI0509553B1 (pt) | 2019-06-18 |
| CN1980898A (zh) | 2007-06-13 |
| MXPA06011141A (es) | 2007-08-14 |
| EP1732902B1 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
| RS20080533A (en) | Triazolopyrazine derivatives useful as anticancer agents | |
| MY143367A (en) | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | |
| TW200510301A (en) | Novel compounds | |
| TW200719886A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| PT1951730E (pt) | Derivados de pirimidina ligados a heteroalquilo | |
| UA87856C2 (ru) | Алкильные производные как модуляторы метаботропных рецепторов глутамата | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
| TW200407305A (en) | Novel compounds | |
| SE0202241D0 (sv) | Novel Compounds | |
| TW200600506A (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
| TW200612936A (en) | Indole derivatives | |
| MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
| MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| MX2009000169A (es) | Derivados de purinona como agonistas de hm74a. | |
| TW200637817A (en) | 5-aminoindole derivatives | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| IL191751A0 (en) | Pyrrolo[2,3-c]pyridine derivatives | |
| NO20065755L (no) | Fôr eller fôrtilsetning inneholdende et alkaloid | |
| TW200626158A (en) | Naphthaline derivatives | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
| MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. |